Live updates

China explosions kill at least two people

Several explosions in China's western region have killed at least two people and injured many others, according to Chinese state media.

The blasts happened in at least three places of Luntai county, according to the Tianshan news portal, which is run by the regional branch of the Communist Party.

"Public security officers quickly handled the situation," it said, without giving details.

The brief statement said the unspecified number of injured had been taken to hospital and an investigation was under way.

Luntai county is in central Xinjiang, 220 miles south-west of the capital, Urumqi.

Xinjiang has experienced rising unrest in recent months blamed on militants from the region's native Muslim Turkic Uighur ethnic group seeking to overthrow Chinese rule.

China fines GlaxoSmithKline £297 million for bribery

GlaxoSmithKline has been fined £297 million and its former country manager handed a suspended prison sentence in China for bribery.

GSK accepted the decision by the Changsha Intermediate People's Court in Hunan province that it had bribed doctors and hospitals to use its products, adding it has taken steps to change its working practices.

ITV News China Correspondent Lucy Watson reports from Beijing:

Advertisement

British GSK exec 'will not face jail time in China'

Mark Reilly, the former China head of British drugmaker GlaxoSmithKline, will be deported from China and will not face jail time in the country, Reuters has reported citing a source with direct knowledge of the matter.

"Reilly will be deported so he won't be in detention in China," said the source with knowledge of the matter who declined to be named because of the sensitivity of the case.

GSK 'will learn from' China bribery investigation

GlaxoSmithKline said a bribery case in China had been a "deeply disappointing matter" after a number of company executives were jailed and the firm was fined £297 million.

GSK said in a statement on their website that the activities by the firm's China unit were a "clear breach" of GSK's governance and compliance procedures.

GSK Chief Executive Officer Sir Andrew Witty said:

Reaching a conclusion in the investigation of our Chinese business is important, but this has been a deeply disappointing matter for GSK. We have and will continue to learn from this.

GSK has been in China for close to a hundred years and we remain fully committed to the country and its people. We will continue to expand access to innovative medicines and vaccines to improve their health and well-being.

We will also continue to invest directly in the country to support the government's health care reform agenda and long-term plans for economic growth.

– Sir Andrew Witty

British GSK executive 'jailed for up to four years'

GlaxoSmithKline executives have been jailed in China. Credit: PA

Former GlaxoSmithKline China chief Mark Reilly and other GSK executives will be jailed for two to four years for paying out bribes, state news agency Xinhua said.

China has fined British pharmaceuticals giant three billion yuan (£297 million) in what is a record penalty for China, Xinhua said.

Advertisement

'GSK executives jailed' in China bribery case

China has fined British drug firm GlaxoSmithKline $492 million and jailed company executives on bribery charges, the Associated Press has reported.

Chinese online giant Alibaba set to break stock record

Chinese tech giant Alibaba is expected to set the price of its shares in what could be a record-breaking initial public offering (IPO).

Jack Ma founded Alibaba 15 years ago. Credit: Reuters

Alibaba is the online shopping leader in China, controlling four-fifths of all e-commerce in the world's second biggest economy. It handles more transactions than Amazon and eBay combined.

But unlike its western rivals, Alibaba does not own most of the goods it sells. Instead, it connects buyers with sellers - some of which offer rather unusual items.

The stock price for when the company enters New York Stock Exchange is expected to range between $66 and $68 a share due to the strong demand.

At the top end of that range, the IPO would raise almost $22 billion (£13.5 billion).

Alibaba plans to expand its business in the United States and Europe after the deal.

Load more updates